QUOTE AND NEWS
Benzinga  Mar 27  Comment 
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist, in...
Benzinga  Feb 11  Comment 
In a report published Monday, Jefferies reiterated its Buy rating on Neurocrine Biosciences (NASDAQ: NBIX), and slightly raised its price target from $13.00 to $14.00. Jefferies noted, “NBIX reported 4Q12 earnings per share and announced 2013...
Benzinga  Feb 11  Comment 
Nasdaq OMX Group (NASDAQ: NDAQ) shares gained 0.68% to create a new 52-week high of $29.67. Nasdaq OMX's PEG ratio is 1.02. PCM (NASDAQ: PCMI) shares created a new 52-week high of $7.123. PCM's trailing-twelve-month revenue is $1.46...
StreetInsider.com  Feb 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Neurocrine+Biosciences+%28NBIX%29+Tops+Q4+EPS+by+22c%2C+Guides+FY13+Below+Street/8073116.html for the full story.
StreetInsider.com  Jan 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Neurocrine+Biosciences+%28NBIX%29+Receives+More+VMAT2+Patents+in+Europe/8026730.html for the full story.
StreetInsider.com  Dec 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Neurocrine+Biosciences+%28NBIX%29+Initiates+NBI-98854+Phase+IIb/7957392.html for the full story.
StreetInsider.com  Nov 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Neurocrine+Biosciences+%28NBIX%29+Files+%24150M+Common+Shelf/7896019.html for the full story.
StreetInsider.com  Oct 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Neurocrine+Biosciences%2C+Inc.+%28NBIX%29+Reports+In-Line+Q3+EPS/7831928.html for the full story.
Benzinga  Oct 4  Comment 
Morgan Stanley initiated its coverage on Neurocrine Biosciences (NASDAQ: NBIX) with an Overweight rating and a $12 price target. Morgan Stanley said, "Neurocrine has a differentiated lead asset, elagolix, targeting large markets with segments...
Benzinga  Oct 1  Comment 
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this twelve-week Phase IIb study...





You may also be interested in articles related to Neurocrine Biosciences (NBIX):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki